Fast sterility testing market seen reaching $1.76 billion by 2030

By AI, Created 4:56 PM UTC, May 18, 2026, /AGP/ – The market for fast sterility testing using ATP bioluminescence is projected to nearly double by 2030 as pharmaceutical, biotech and food safety users look for faster contamination detection. North America led in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Fast sterility testing with ATP bioluminescence gives manufacturers a quicker read on microbial contamination than traditional culture-based tests. - The method can support faster release decisions, tighter quality control and stronger regulatory compliance in pharmaceuticals, biotechnology and food and beverage safety testing. - The market’s growth signals a broader shift toward rapid microbial detection and automated monitoring tools.

What happened: - The Business Research Company released a 2026 market report on fast sterility testing by adenosine triphosphate bioluminescence. - The report estimates the market will rise from $0.96 billion in 2025 to $1.08 billion in 2026. - The report projects the market will reach $1.76 billion by 2030. - The report forecasts a 12.7% CAGR for the historical period and a 12.9% CAGR through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - ATP bioluminescence testing detects microbial contamination by measuring ATP, an energy molecule found in living cells. - The luciferase enzyme triggers a light-producing reaction with ATP. - The resulting light output gives an almost immediate sterility assessment. - The report links historical market growth to the need for faster sterility testing in pharmaceuticals, limits of culture-based techniques, tighter contamination-prevention rules, growth in biotech manufacturing and hospital infection control programs. - The forecast is driven by automated rapid testing platforms, investment in microbial detection technology, food and beverage safety testing, expansion of cleanroom production and more emphasis on quality assurance. - Key trends include broader use of rapid microbial detection, more real-time sterility monitoring, wider adoption of luminometer-based systems, growth in automated bioluminescence analyzers and gradual replacement of culture-based methods. - The pharmaceutical and biotechnology industries are major demand drivers because both sectors need quick contamination screening to protect product safety and production speed. - Eurostat reported in April 2025 that EU exports of medicinal and pharmaceutical products rose 13.5% in 2024 to $316.38 billion (€313.4 billion). - The UK BioIndustry Association said in January 2025 that biotech sector investments climbed 94% in 2024 to £3.5 billion, about $4.4 billion. - The report also includes sample and full-report links from The Business Research Company: Download a free sample and View the full report.

Between the lines: - The forecast suggests buyers are moving away from slower culture-based methods as speed and automation become more valuable. - Rising investment in biotech and pharmaceutical production is likely to keep demand focused on contamination testing that fits modern manufacturing timelines. - The strongest near-term opportunity appears to be in regions expanding regulated production capacity and cleanroom operations.

What’s next: - The report points to continued adoption of rapid microbial detection platforms and luminometer-based systems. - Market growth is likely to track expansion in pharmaceutical manufacturing, biotech output and food safety testing requirements. - Asia-Pacific’s expected growth suggests the competitive center of the market may shift as production footprints expand in the region.